AMTB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMTB is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mixed setup: fundamentals improved sharply in Q1 2026, but price action is only neutral and the buy signals are absent. With no clear bullish catalyst and analysts still only at Market Perform, the better call is to hold and wait for a clearer entry rather than buy aggressively now.
Current price is 23.38, basically flat on the day, with the market closed. The trend is mixed-to-neutral. MACD histogram is negative at -0.0768, though it is contracting, which suggests downside momentum is easing. RSI_6 at 60.544 is neutral-to-slightly positive, not overbought. Moving averages are converging, which usually signals a lack of strong directional trend. Price is sitting near pivot 22.912 and just below resistance 23.6, with further resistance at 24.024. Support is at 22.224 and 21.8. The stock trend model suggests modest short-term upside, but not enough to call it a high-conviction buy.
["Q1 2026 net income rose 49.46% YoY.", "Q1 2026 EPS rose 57.14% YoY to 0.44.", "Options positioning is mildly bullish with a 0.35 put-call open interest ratio.", "Analyst price target was raised to $24 from $23."]
["Revenue fell 4.44% YoY in Q1 2026.", "MACD remains below zero, indicating lingering bearish momentum.", "No recent news catalysts in the past week.", "Hedge funds have been selling heavily, with selling up 1633.98% over the last quarter.", "Analyst rating remains only Market Perform, not a bullish call.", "No AI Stock Picker signal and no recent SwingMax signal."]
In Q1 2026, Amerant Bancorp showed strong bottom-line improvement despite weaker top-line performance. Revenue declined to 90.28 million, down 4.44% YoY, but net income increased to 17.87 million, up 49.46% YoY, and EPS rose 57.14% YoY to 0.44. For a bank, improving earnings and EPS are positive, but the revenue decline suggests growth is not yet broadly strong. Overall, the latest quarter was financially better on profitability than on sales growth.
Recent analyst sentiment is mildly positive but still cautious. On 2026-04-28, Keefe Bruyette raised the price target to $24 from $23 while keeping a Market Perform rating. That means Wall Street sees limited upside and is not calling for outperformance. Pros: slightly higher target, improved earnings trend. Cons: still neutral rating, no strong bullish consensus, and the target is only modestly above the current price.
